In recent trading session, Evaxion Biotech A/S ADR (NASDAQ:EVAX) saw 0.76 million shares changing hands at last check today with its beta currently measuring -0.24. Company’s recent per share price level of $2.41 trading at -$0.98 or -28.76% at last check today assigns it a market valuation of $2.83M. That most recent trading price of EVAX’s stock is at a discount of -1225.73% from its 52-week high price of $31.95 and is indicating a premium of 1.24% from its 52-week low price of $2.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.56 million shares which gives us an average trading volume of 1.15 million if we extend that period to 3-months.

For Evaxion Biotech A/S ADR (EVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.

Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information

Upright in the red during last session for losing -28.76%, in the last five days EVAX remained trading in the red while hitting it’s week-highest on Friday, 01/24/25 when the stock touched $2.41 price level, adding 75.41% to its value on the day. Evaxion Biotech A/S ADR’s shares saw a change of -42.87% in year-to-date performance and have moved -33.65% in past 5-day. Evaxion Biotech A/S ADR (NASDAQ:EVAX) showed a performance of -54.43% in past 30-days. Number of shares sold short was 0.1 million shares which calculate 1.07 days to cover the short interests.

Evaxion Biotech A/S ADR (EVAX) estimates and forecasts

Statistics highlight that Evaxion Biotech A/S ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -82.44% of value to its shares in past 6 months, showing an annual growth rate of 89.38% while that of industry is 16.10. Apart from that, the company came raising its revenue forecast for fiscal year 2025.

2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.66M for the same. And 1 analysts are in estimates of company making revenue of 3.2M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -18.88% during past 5 years.